Author: Extermann, Martine ; Marshall, Victoria K ; Ligatti, Jay ; Szalacha, Laura A ; Mason, Tina M ; Menon, Usha ; Chavez, Melody N ; Simon, Lanie A

INTRODUCTIONOlder adults are often prescribed oral anticancer agents (OAAs). Technology-based interventions may offer medication and symptom support. We aimed to evaluate technology ownership, use, and preferred design features of a supportive web-based program using a multimethod design utilizing surveys and semi-structured interviews.MATERIALS AND METHODSPatients were recruited from a National Cancer Institute-designated Comprehensive Cancer Center. Eligibility included those: (1) ≥65 years of age; (2) prescribed a Food and Drug Administration-approved OAA; (3) English speaking; (4) able/willing to complete telephone interviews. Interviews were audio-recorded and transcribed verbatim. Cohen's Kappa was used to evaluate inter-rater reliability and calculated at 0.87.RESULTSParticipants (N = 30) were predominantly female (70 %), White (83.3 %), with metastatic disease (90 %). The mean age was 74.9 years. Ninety percent owned a smartphone, 66.7 % owned a tablet, and 90 % owned a computer. Nearly 57 % reported using smartphones frequently for cancer-related purposes. Four themes with corresponding subthemes were identified: (1) comfort with technology; (2) reasons for technology use for health-related purposes (research of cancer, cancer treatment, and related symptoms/side effects; using the portal to manage health; and appointment and medication reminders); (3) recommended design features for a web-based program (OAA medication-specific information; calendars & medication alarms/reminders; symptom management & symptom trackers; and tutorials and testimonials); and (4) adaptations for older adults (simple navigation; larger font; use of layperson's terms; use of pictures, graphics, and color coding; and voice activation).DISCUSSIONOlder adults use technology for health-related purposes. Specific web-design features and adaptations are needed to enhance usability among older adults.

01 Feb 2025·CNS Neuroscience & Therapeutics

Physical Activities and Parkinson's Disease Progression: A Two‐Sample Mendelian Randomization Study

Article

Author: Xue, Cheng ; Liu, Zheng ; Hao, Zhongnan ; Xin, Wenqiang ; Xiao, Zhipeng ; Luo, Xiaoyue ; Li, Meihua ; Lu, Guohui ; Zheng, Zijian ; Wei, Wei ; Pan, Yongli

ABSTRACTAimsTo explore the causal relationship between physical activity (PA) and the progression of Parkinson's disease (PD), we conducted a two‐sample Mendelian randomization (MR) analysis.MethodsGenetic variants were obtained from publicly available genome‐wide association study (GWAS) summary statistics for PA (N = 377,000), age at onset (N = 28,568), and PD progression (N = 4093). Causal estimates were calculated using the inverse variance weighted (IVW) method, with MR‐Egger and weighted median analyses performed to assess the robustness of the results.ResultsGenetically predicted accelerometer‐based overall acceleration average (OAA) was associated with a reduced risk of constipation in PD progression (OR: 0.60, 95% CI: 0.42–0.86, p = 5.50 × 10−3). Moderate‐to‐vigorous physical activity (MVPA) demonstrated a similar but stronger effect on constipation risk (OR: 0.03, 95% CI: 9.38 × 10−4–0.90, p = 0.043). Additionally, OAA showed a protective effect on motor experiences of daily living (OR: 0.84, 95% CI: 0.71–1.00, p = 0.046). No causal effects were identified for vigorous physical activity (VPA) or the fraction of accelerations exceeding 425 milligravities (FAA) on PD progression.ConclusionOur findings suggest a negative causal relationship between PA and PD progression, highlighting the potential role of physical activity in guiding therapeutic strategies for PD management.

01 Jan 2025·Clinical Lymphoma Myeloma and Leukemia

Enhancing Multiple Myeloma Care: Implementation of Pharmacist-Led Prescribing of Immunomodulatory Drugs in an Academic Medical Setting

Article

Author: Portuguese, Andrew J ; Banerjee, Rahul ; Indorf, Amy ; Chen, Ashley ; Jao, Mark ; Cowan, Andrew J ; Segal, Eve M ; Baek, Grace T ; Yoon, Linda ; Kwok, Mary ; Cicero, Kara I

BACKGROUNDThe oncology healthcare landscape has transformed and has demonstrated the need for efficient care delivery models due to improved survival resulting in larger patient panels. Pharmacists can prescribe oral anticancer agents (OAA), laboratory orders, and supportive care treatments as licensed independent practitioners (LIP) under their pharmacist license. Using immunomodulators (IMiDs) for patients with multiple myeloma (MM) has complexities with regulatory requirements for prescribing. At our institution, the care team was spending about 240 hours per month satisfying regulatory activities. We aim to characterize the effectiveness of pharmacist LIPs for patients with MM receiving IMiD treatment.METHODSA multidisciplinary quality improvement team implemented a model for OAA management with pharmacist LIPs. Patients were evaluated for IMiD adherence. Medication possession ratios (MPR) were collected using fill history for patients with 6 months of fill history pre and postpharmacist LIPs involvement, and paired McNemar's Test assessed differences in adherence. A care team survey gauged satisfaction.RESULTSThe pharmacist patient panel comprised 246 patients. There were similar adherence rates, with an MPR of 96% preintervention and 96.55% postintervention. All survey participants recommended the pharmacist prescriber for IMiDs and reported positive reviews of pharmacist involvement.CONCLUSIONManagement of OAAs by pharmacist LIPs is viable clinical model. The care team reduced their administrative burden while empowering pharmacists to practice at the top of their license. This framework serves as a guide for institutions to adapt and optimize OAA management in an increasingly complex therapeutic landscape.

100 Deals associated with Oleanolic Acid Acetate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	South Korea	Korea Research Institute of Bioscience & Biotechnology	18 Apr 2024
Nephrotoxicity	Preclinical	South Korea	Korea Research Institute of Bioscience & Biotechnology	18 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Oleanolic Acid Acetate

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation